Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: The role of inflammation

Cardiovascular Drugs and Therapy

Volumn 23, Issue 5, 2009, Pages 369-376

  Liu, Miao ^a   Wang, Fang ^a   Wang, Yanrong ^a   Jin, Runming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atorvastatin; Dilated cardiomyopathy; Endothelial function; Soluble intercellular adhesion molecule 1

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HEART RATE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASCULITIS; WALKING;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOMYOPATHY, DILATED; CHOLESTEROL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; EXERCISE; EXERCISE TEST; FEMALE; HEART FUNCTION TESTS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PROSPECTIVE STUDIES; PYRROLES; VASODILATION; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 72849122047     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6186-3     Document Type: Article

References (26)

1. R Celis G Torre-Martinez G Torre-Amione 2008 Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol 23 254 60 10.1097/HCO.0b013e3282fbfbc7 18382215
2. CP Dahl L Gullestad B Fevang AM Holm L Landro LE Vinge, et al. 2008 Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure Eur J Heart Fail 10 352 9 10.1016/j.ejheart.2008.02.010 1:CAS:528:DC%2BD1cXksVaks7s%3D 18353719
3. S Sola MQ Mir S Lerakis N Tandon BV Khan 2006 Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure J Am Coll Cardiol 47 332 7 10.1016/j.jacc.2005.06.088 1:CAS:528:DC%2BD28XksFCnsA%3D%3D 16412856 (Pubitemid 43063250)
4. CH Strey JM Young JH Lainchbury CM Frampton MG Nicholls AM Richards, et al. 2006 Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure Heart 92 1603 9 10.1136/hrt.2005.082560 1:CAS:528: DC%2BD28Xht12qtLvL 16709697 (Pubitemid 44629164)
5. KK Khush DD Waters V Bittner PC Deedwania JJ Kastelein SJ Lewis, et al. 2007 Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study Circulation 115 576 83 10.1161/CIRCULATIONAHA.106.625574 1:CAS:528:DC%2BD2sXhtVyis74%3D 17261662 (Pubitemid 46226167)
6. J Kjekshus E Apetrei V Barrios M Bohm JG Cleland JH Cornel, et al. 2007 Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2248 61 10.1056/NEJMoa0706201 1:CAS:528:DC%2BD2sXhsVSlsLvI 17984166 (Pubitemid 350190755)
7. L Tavazzi AP Maggioni R Marchioli S Barlera MG Franzosi R Latini, et al. 2008 Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 1231 9 10.1016/S0140-6736(08)61240-4 18757089
8. I Kovacs J Toth J Tarjan A Koller 2006 Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE Eur J Heart Fail 8 451 9 10.1016/j.ejheart.2005.10.011 1:CAS:528:DC%2BD28XotlCjtrg%3D 16325470 (Pubitemid 44236167)
9. V Videm M Albrigtsen 2008 Soluble ICAM-1 and VCAM-1 as markers of endothelial activation Scand J Immunol 67 523 31 10.1111/j.1365-3083.2008.02029. x 1:CAS:528:DC%2BD1cXmtFOgtbw%3D 18363595
10. MC Corretti TJ Anderson EJ Benjamin D Celermajer F Charbonneau MA Creager, et al. 2002 Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 257 65 10.1016/S0735-1097(01)01746-6 11788217 (Pubitemid 34084631)
11. B Hesse TB Lindhardt W Acampa C Anagnostopoulos J Ballinger JJ Bax, et al. 2008 EANM/ESC guidelines for radionuclide imaging of cardiac function Eur J Nucl Med Mol Imaging 35 851 85 10.1007/s00259-007-0694-9 1:STN:280: DC%2BD1c7ovFentw%3D%3D 18224320
12. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
13. S Jonsdottir KK Andersen AF Sigurosson SB Sigurosson 2006 The effect of physical training in chronic heart failure Eur J Heart Fail 8 97 101 10.1016/j.ejheart.2005.05.002 16194620 (Pubitemid 43012107)
14. WH Yin JW Chen HL Jen MC Chiang WP Huang AN Feng, et al. 2003 The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure Eur J Heart Fail 5 507 16 10.1016/S1388- 9842(03)00009-6 1:CAS:528:DC%2BD3sXmt1Kitbs%3D 12921812 (Pubitemid 37021645)
15. M Cugno D Mari PL Meroni E Gronda F Vicari M Frigerio, et al. 2004 Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation Br J Haematol 126 85 92 10.1111/j.1365-2141.2004.04977.x 1:CAS:528:DC%2BD2cXmtl2rt7k%3D 15198737 (Pubitemid 38859487)
16. D Fischer S Rossa U Landmesser S Spiekermann N Engberding B Hornig, et al. 2005 Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death Eur Heart J 26 65 9 10.1093/eurheartj/ehi001 1:STN:280:DC%2BD2cnktVWjsw%3D%3D 15615801 (Pubitemid 40221125)
17. J Bauersachs K Hiss D Fraccarollo U Laufs H Ruetten 2006 Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects Cardiovasc Res 72 438 46 10.1016/j.cardiores.2006.08.014 1:CAS:528:DC%2BD28XhtFKmtb3F 17026973 (Pubitemid 44665849)
18. M Takemoto K Node H Nakagami Y Liao M Grimm Y Takemoto, et al. 2001 Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 108 1429 37 1:CAS:528:DC%2BD3MXosVyrur4%3D 11714734
19. DJ Mulder PL van Haelst MH Wobbes RO Gans F Zijlstra JF May, et al. 2007 The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress Cardiovasc Drugs Ther 21 91 7 10.1007/s10557-007-6010-x 1:CAS:528:DC%2BD2sXlslOgtrc%3D 17342417 (Pubitemid 46834905)
20. O Hernandez-Perera D Perez-Sala J Navarro-Antolin R Sanchez-Pascuala G Hernandez C Diaz, et al. 1998 Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 2711 9 10.1172/JCI1500 1:CAS:528:DyaK1cXktVSiurw%3D 9637705
21. P Nachtigal N Pospisilova G Jamborova K Pospechova D Solichova C Andrys, et al. 2008 Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice Life Sci 82 708 17 10.1016/j.lfs.2008.01. 006 1:CAS:528:DC%2BD1cXjtl2rt7Y%3D 18289605
22. AL Graciano DD Bryant DJ White J Horton NE Bowles BP Giroir 2001 Targeted disruption of ICAM-1, P-selectin genes improves cardiac function and survival in TNF-alpha transgenic mice Am J Physiol Heart Circ Physiol 280 H1464 71 1:CAS:528:DC%2BD3MXjtV2jtbw%3D 11247755
23. R Wojnicz K Wilczek E Nowalany-Kozielska B Szygula-Jurkiewicz J Nowak L Polonski, et al. 2006 Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels Am J Cardiol 97 899 904 10.1016/j.amjcard.2005.09.142 1:CAS:528:DC%2BD28XitVehtr8%3D 16516598 (Pubitemid 43313268)
24. K Node M Fujita M Kitakaze M Hori JK Liao 2003 Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 839 43 10.1161/01.CIR.0000084539.58092.DE 1:CAS:528:DC%2BD3sXmtFCisbc%3D 12885745 (Pubitemid 37022126)
25. R Lee YH Chan J Wong D Lau K Ng 2007 The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy: a study of the multiracial population in Singapore Int J Cardiol 119 168 75 10.1016/j.ijcard.2006.07.189 17056135 (Pubitemid 46818517)
26. AJ Jordan MP Anguita 2009 Effect of statin treatment on mortality in a large cohort of heart failure patients Rev Esp Cardiol 62 323 7 10.1016/S1885-5857(09)71565-8 19268080